Ten-year outcome of Eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome– a single center experience
2020 · BMC Nephrology · 22 citations
https://doi.org/10.1186/s12882-020-01847-0
S
Sam Kant
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
92
Papers
846
Citations
16
h-index
23
i10-index
Sam Kant is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Vasculitis and related conditions & Renal Transplantation Outcomes and Treatments & Renal Diseases and Glomerulopathies. The author has an h-index of 16, co-authored 79 publications.
ORCID: 0000-0001-5863-3562Papers by this author
worksTiming of COVID-19 Vaccine in the Setting of Anti-CD20 Therapy: A Primer for Nephrologists
2021 · Kidney International Reports · 22 citations
https://doi.org/10.1016/j.ekir.2021.03.876
SARS-CoV-2 Vaccine Response in Patients With Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis
2021 · Kidney International Reports · 11 citations
https://doi.org/10.1016/j.ekir.2021.12.004
ANCA Vasculitis Induction Management During the COVID-19 Pandemic
2021 · Kidney International Reports · 9 citations
https://doi.org/10.1016/j.ekir.2021.08.009
Subcutaneous Immunoglobulin for Antibody Deficiency in Antineutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis
2019 · Cureus · 7 citations
https://doi.org/10.7759/cureus.6367
Utility of Donor-Derived Cell-Free DNA in Detecting ABMR in Patients With AT1R Antibodies
2021 · Kidney International Reports · 5 citations
https://doi.org/10.1016/j.ekir.2021.07.026
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat